Analysis of adverse reactions of bevacizumab-induced osteonecrosis and pharmaceutical care
- VernacularTitle:贝伐珠单抗致骨坏死的不良反应分析及药学监护
- Author:
Lei WANG
1
;
Zhonghua FU
1
;
Zuxuan SHI
2
;
Chenglong ZHAO
1
Author Information
1. Dept. of Pharmacy，Henan Provincial People’s Hospital，Zhengzhou 450003，China
2. Cancer Center，Henan Provincial People’s Hospital，Zhengzhou 450003，China
- Publication Type:Journal Article
- Keywords:
femoral head necrosis;
bevacizumab;
FAERS;
adverse reactions
- From:
China Pharmacy
2024;35(22):2828-2831
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide a reference for accurately identifying and treating adverse reactions of osteonecrosis induced by bevacizumab. METHODS Clinical pharmacists participated in the treatment process of an adult patient with glioma who developed femoral head necrosis after the use of bevacizumab. By searching the FDA Adverse Event Reporting System （FAERS） and consulting relevant literature and drug instructions， the association between femoral head necrosis and bevacizumab was assessed. Medication recommendations were provided to the physician， and medication educations were provided to the patient. RESULTS The association between the patient’s femoral head necrosis and bevacizumab was assessed as “possibly related”. The physicians accepted the clinical pharmacists’ advice to discontinue bevacizumab and switched to anlotinib to continue antitumor treatment. The patient also followed the clinical pharmacists’ advice to avoid prolonged standing. Upon re-examination， the patient’s pain symptoms were under control， and the femoral head necrosis had not progressed. CONCLUSIONS Patients who receive long-term bevacizumab should attach great importance to bone pain and osteonecrosis， undergo regular imaging examinations， and detect and treat symptoms early to prevent the occurrence of severe osteonecrosis.
